

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =punti0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Amparore Daniele	RTDB	MED/24	2318/1828879	2021	Three-dimensional Virtual Models' Assistance During Minimally Invasive Partial Nephrectomy Minimizes the Impairment of Kidney Function	No fondi = si applica moltiplicatore 1,25	3	1			4	31	38,75	8.882,52 €
Amparore Daniele	RTDB	MED/24	2318/1738064	2020	Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres	Co-first	3	1		0,5	2			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1738093	2020	Impact of the COVID-19 pandemic on urology residency training in Italy.	Fist e corresponding	2	1			3			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1710001	2018	3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction.		3	0			3			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1710002	2018	Hyperaccuracy Three-dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping During Robot-assisted Partial Nephrectomy for Complex Renal Masses.	Q1 non top 10 su scopus q2 su wos	2	0			2			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1711053	2019	Three-dimensional virtual imaging of renal tumours: a new tool to improve the accuracy of nephrometry scores.		3	0			3			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1721127	2020	Robot-assisted Partial Nephrectomy for Complex (PADUA Score ≥10) Tumors: Techniques and Results from a Multicenter Experience at Four High-volume Centers		3	0			3			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1870380	2021	Comparison between minimally-invasive partial and radical nephrectomy for the treatment of clinical T2 renal masses: results of a 10-year study in a tertiary care center		3	1			4			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1870381	2021	3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction		3	1			4			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1870382	2021	3D imaging technologies in minimally invasive kidney and prostate cancer surgery: which is the urologists' perception?		2	1			3			0,00 €
Arena Sabrina	PA	BIO/17	2318/1796060	2021	Empowering clinical decision-making in oligometastatic colorectal cancer: the potential role of drug screening of patient-derived organoids	No fondi. last and corresponding	1	1			2	25,5	31,875	7.306,59 €
Arena Sabrina	PA	BIO/17	2318/1792656	2021	Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.	last and corresponding	3	1		0,5	2			0,00 €
Arena Sabrina	PA	BIO/17	2318/1792657	2021	Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy	middle	3	0	0,5		1,5			0,00 €
Arena Sabrina	PA	BIO/17	2318/1740015	2020	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer	middle	3	0	0,5		1,5			0,00 €
Arena Sabrina	PA	BIO/17	2318/1764704	2020	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer.	co-first and co-corresponding	3	1			4			0,00 €
Arena Sabrina	PA	BIO/17	2318/1738329	2020	Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer.	last and corresponding	2	1			3			0,00 €
Arena Sabrina	PA	BIO/17	2318/1728652	2020	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clin Cancer Res.	first	3	1			4			0,00 €

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Arena Sabrina	PA	BIO/17	2318/1675614	2019	Adaptive mutability of colorectal cancers in response to targeted therapies.	Titolo e codice non corrispondono, ma punteggio uguale per entrambi.middle	3	0	0,5		1,5			0,00 €
Arena Sabrina	PA	BIO/17	2318/1715076	2019	Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer.	last and corresponding	3	1			4			0,00 €
Arena Sabrina	PA	BIO/17	2318/1689587	2018	Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer.	First	1	1			2			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794750	2020	Future perspectives from lung cancer pre-clinical models: new treatments are coming?	No fondi attivi alla scadenza del bando	2	1		0,5	1,5	14,5	18,125	4.154,73 €
Bersani Francesca	RTDA	BIO/10	2318/1794956	2020	Water and microbial monitoring technologies towards the near future space exploration		3	0		0,5	1,5			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794730	2020	Water disinfection by orifice-induced hydrodynamic cavitation		3	0			3			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794732	2020	Techno-economic analysis of a solar thermal plant for large-scale water pasteurization		1	0			1			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794764	2019	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer		3	0	0,5		1,5			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794753	2018	Screening and risk management solutions for steroidal estrogens in surface and wastewater		3	0		0,5	1,5			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794925	2018	Effect-based and chemical analytical methods to monitor estrogens under the European Water Framework Directive		3	0		0,5	1,5			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794729	2018	Water quality and total microbial load: A double-threshold identification procedure intended for space applications		2	0			2			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794754	2018	AR expression in breast cancer CTCs associates with bone metastases		2	0	0,5		1			0,00 €
Bersani Francesca	RTDA	BIO/10												0,00 €
Bertotti Andrea	PA	BIO/17	2318/1774807	2020	Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.	Fondi attivi = non si applica moltiplicatore	2	0	0,5		1	19,5	19,5	4.469,91 €
Bertotti Andrea	PA	BIO/17	2318/1797853	2021	Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling		3	0	0,5		1,5			0,00 €
Bertotti Andrea	PA	BIO/17	2318/1768036	2021	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts		3	0	0,5		1,5			0,00 €
Bertotti Andrea	PA	BIO/17	2318/1750197	2020	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype	Co-last	3	1			4			0,00 €
Bertotti Andrea	PA	BIO/17	2318/1740015	2020	EGFR Blockade Reverts Resistance to KRAS G12C Inhibition in Colorectal Cancer		3	0	0,5		1,5			0,00 €
Bertotti Andrea	PA	BIO/17	2318/1725664	2019	Adaptive mutability of colorectal cancers in response to targeted therapies		3	0	0,5		1,5			0,00 €
Bertotti Andrea	PA	BIO/17	2318/1714058	2019	Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens		3	0	0,5		1,5			0,00 €
Bertotti Andrea	PA	BIO/17	2318/1675615	2018	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer		3	0	0,5		1,5			0,00 €
Bertotti Andrea	PA	BIO/17	2318/1642129	2017	Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer		3	1			4			0,00 €
Bertotti Andrea	PA	BIO/17	2318/1624823	2017	Interrogating open issues in cancer precision medicine with patient-derived xenografts		3	0		0,5	1,5			0,00 €

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

[illegible]

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =punti0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Buttiglieri Consuelo	PA	MED/06	2318/1769901	2020	On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2	Fondi attivi. Letter per wos e Scopus. Comment per pubmed. Definita Letter sul documento stesso. Sarebbe stato un top10 con posizione autoriale	0	0			0	20	20	4.584,53 €
Buttiglieri Consuelo	PA	MED/06	2318/1769906	2020	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives	corresponding author	3	1		0,5	2			0,00 €
Buttiglieri Consuelo	PA	MED/06	2318/1622315	2017	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel		2	1			3			0,00 €
Buttiglieri Consuelo	PA	MED/06	2318/1679851	2018	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel		2	1			3			0,00 €
Buttiglieri Consuelo	PA	MED/06	2318/1679745	2019	Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer		2	1			3			0,00 €
Buttiglieri Consuelo	PA	MED/06	2318/1675420	2018	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences		3	1		0,5	2			0,00 €
Buttiglieri Consuelo	PA	MED/06	2318/1623655	2017	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer		3	1		0,5	2			0,00 €
Buttiglieri Consuelo	PA	MED/06	2318/1799984	2021	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial		3	0	0,5		1,5			0,00 €
Buttiglieri Consuelo	PA	MED/06	2318/1793553	2021	Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC		3	1		0,5	2			0,00 €
Buttiglieri Consuelo	PA	MED/06	2318/1869806	2021	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications		2	1		0,5	1,5			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1619972	2017	Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer	No fondi attivi. Co-first	3	1			4	19	23,75	5.444,13 €
Comunanza Valentina	RTDB	BIO/10	2318/1653399	2017	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment		2	0	0,5		1			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1623496	2017	VEGF blockade enhances the antitumor effect of BRAFV600E inhibition		3	1			4			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1660655	2017	Therapy for cancer: Strategy of combining anti-angiogenic and target therapies		1	1		0,5	1			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1662906	2018	PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations article		2	0			2			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1685458	2019	TFEB controls vascular development by regulating the proliferation of endothelial cells		3	0	0,5		1,5			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1711992	2019	Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma		3	0	0,5		1,5			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1711962	2020	Wnt/IL-1 $\beta$ /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5		2	0	0,5		1			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1789506	2021	The role of redox system in metastasis formation	Co-first	3	1		0,5	2			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1790637	2021	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma		2	0	0,5		1			0,00 €
Corso Simona	PA	BIO/17	2318/1797848	2021	Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas	Fondi attivi. First Author	3	1			4	31		7.212,80 €
Corso Simona	PA	BIO/17	2318/1795119	2021	Personalized therapeutic strategies in HER2-driven gastric cancer	Co-last Author (see attached publication)	3	1			4			0,00 €

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Corso Simona	PA	BIO/17	2318/1768036	2021	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts		3	1			4			0,00 €
Corso Simona	PA	BIO/17	2318/1847665	2021	Microsatellite instability in Gastric Cancer: Between lights and shadows		3			0,5	1,5			0,00 €
Corso Simona	PA	BIO/17	2318/1799551	2020	Autocrine signaling of NRP1 ligand galectin-1 elicits resistance to BRAF-targeted therapy in melanoma cells		2	0			2			0,00 €
Corso Simona	PA	BIO/17	2318/1717860	2019	A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits.	First Author	3	1			4			0,00 €
Corso Simona	PA	BIO/17	2318/1660557	2018	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.		3	0	0,5		1,5			0,00 €
Corso Simona	PA	BIO/17	2318/1664042	2018	Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts.	First Author	1	1			2			0,00 €
Corso Simona	PA	BIO/17	2318/1691738	2018	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies.	Last Author	3	1			4			0,00 €
Corso Simona	PA	BIO/17	2318/1589685	2017	Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.	Co-last Author (see attached publication)	3	1			4			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1869239	2021	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas.	No fondi attivi	3	0		0,5	1,5	25,5	31,875	7.306,59 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1757318	2020	CSPG4-Specific CAR CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes		3	0	0,5		1,5			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1869240	2020	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.		3	0	0,5		1,5			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1744216	2020	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights.	Co-last	2	1			3			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1869278	2020	Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US Study) from the Italian Sarcoma Group.	Co-first	3	1			4			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1793371	2020	High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series.		1	0	0,5		0,5			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1869280	2020	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.		3	1			4			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1869220	2018	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.	Co-first	3	1			4			0,00 €

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1636089	2017	Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour		3	1			4			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1636100	2017	PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.		3	0	0,5		1,5			0,00 €
Di Blasio Laura	TR		2318/153017	2017	Gelatin Based Hydrogel as Delivery System for Vascular Endothelial Growth Factor Release in Peripheral Nerve Tissue Engineering.	No fondi attivi	2	0			2	15,75	19,6875	4.512,89 €
Di Blasio Laura	TR		2318/1634516	2017	Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination.		2	1		0,5	1,5			0,00 €
Di Blasio Laura	TR		2318/1661645	2017	The AGMA1 polyamidoamine mediates the efficient delivery of siRNA.		2	0			2			0,00 €
Di Blasio Laura	TR		2318/1662907	2018	MRCR $\alpha$ is activated by caspase cleavage to assemble an apical actin ring for epithelial cell extrusion.		3	0			3			0,00 €
Di Blasio Laura	TR		2318/1662906	2018	PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.	First e corresponding	2	1			3			0,00 €
Di Blasio Laura	TR		2318/1696569	2019	Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3 $\beta$ signaling and inhibition of cellular prostatic acid phosphatase.		3	0	0,5		1,5			0,00 €
Di Blasio Laura	TR		2318/1729756	2019	Dynamic Interplay between Pericytes and Endothelial Cells during Sprouting Angiogenesis.		1	0			1			0,00 €
Di Blasio Laura	TR		2318/1729742	2020	Activation of RSK by Phosphomimetic Substitution in the Activation Loop Is Prevented by Structural Constraints.		3	0	0,5		1,5			0,00 €
Di Blasio Laura	TR		2318/1775041	2021	A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome.		0,5	0	0,5		0,25			0,00 €
Di Blasio Laura	TR													0,00 €
Doronzo Gabriella	TR		2318/1869779	2021	TFEB Signalling-Related MicroRNAs and Autophagy.	No fondi. Co-last	1	1		0,5	1	8,5	10,625	2.435,53 €
Doronzo Gabriella	TR		2318/1789507	2021	The Oncogene Transcription Factor EB Regulates Vascular Functions.	First	2	1		0,5	1,5			0,00 €
Doronzo Gabriella	TR		2318/1788049	2021	Multifaceted activities of transcription factor EB in cancer onset and progression.	Last	3	1		0,5	2			0,00 €
Doronzo Gabriella	TR		2318/1685458	2019	TFEB controls vascular development by regulating the proliferation of endothelial cells.	First	3	1			4			0,00 €
Doronzo Gabriella	TR													0,00 €
Doronzo Gabriella	TR													0,00 €
Doronzo Gabriella	TR													0,00 €
Doronzo Gabriella	TR													0,00 €
Doronzo Gabriella	TR													0,00 €
Doronzo Gabriella	TR													0,00 €
Doronzo Gabriella	TR													0,00 €
Germano Antonina	TR		2318/1742712	2020	Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma	No fondi attivi. First name	1	1			2	12	15	3.438,40 €
Germano Antonina	TR		2318/1693660	2018	Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas		3	0	0,5		1,5			0,00 €
Germano Antonina	TR		2318/1687226	2018	CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells	First name	3	1			4			0,00 €
Germano Antonina	TR		2318/1641067	2017	Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma	First name	2	1			3			0,00 €

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

[illegible]

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Maione Federica	RTDA	BIO/12		2022	Inducible T-Cell Costimulator Ligand Plays a Dual Role in Melanoma Metastasis upon Binding to Osteopontin or Inducible T-Cell Costimulator	No fondi attivi	1	0	0,5		0,5	19,5	24,375	5.587,39 €
Maione Federica	RTDA	BIO/12		2021	Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance		1	0			1			0,00 €
Maione Federica	RTDA	BIO/12		2020	Osteopontin binds ICOSL promoting tumor metastasis		3	0	0,5		1,5			0,00 €
Maione Federica	RTDA	BIO/12		2020	HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction	Co-first	1	1			2			0,00 €
Maione Federica	RTDA	BIO/12		2020	CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth		3	0	0,5		1,5			0,00 €
Maione Federica	RTDA	BIO/12		2018	A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent.	Co-first	3	1			4			0,00 €
Maione Federica	RTDA	BIO/12		2018	Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.		3	0			3			0,00 €
Maione Federica	RTDA	BIO/12		2017	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth		3	0	0,5		1,5			0,00 €
Maione Federica	RTDA	BIO/12		2017	Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program	Co-last	3	1			4			0,00 €
Maione Federica	RTDA	BIO/12		2017	Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy		1	0	0,5		0,5			0,00 €
Merlini Alessandra	RTDA	MED/06	2318/1835722	2021	Parp1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas—a preclinical and translational study.	No fondi. Corresponding	2	1			3	13	16,25	3.724,93 €
Merlini Alessandra	RTDA	MED/06	2318/1869107	2021	Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study.		2	0	0,5		1			0,00 €
Merlini Alessandra	RTDA	MED/06	2318/1835642	2021	Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing's sarcoma and chondrosarcoma.	Co-first	1	1			2			0,00 €
Merlini Alessandra	RTDA	MED/06	2318/1844352	2021	Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors		3	0	0,5		1,5			0,00 €
Merlini Alessandra	RTDA	MED/06	2318/1744216	2020	Pazopanib and trametinib as a synergistic strategy against osteosarcoma: preclinical activity and molecular insights.		2	0	0,5		1			0,00 €
Merlini Alessandra	RTDA	MED/06	2318/1757318	2020	CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes.		3	0	0,5		1,5			0,00 €
Merlini Alessandra	RTDA	MED/06	2318/1723160	2020	Response to Eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.	corresponding author	0,5	0,5			1			0,00 €
Merlini Alessandra	RTDA	MED/06	2318/1793372	2020	Delving into PARP inhibition from bench to bedside and back.	Co-first	3	1		0,5	2			0,00 €
Merlini Alessandra	RTDA	MED/06												0,00 €
Merlini Alessandra	RTDA	MED/06												0,00 €
Migliore Cristina	RTDA	BIO/17	2318/1795119	2021	Personalized therapeutic strategies in HER2-driven gastric cancer	No fondi. Co-first	3	1			4	22	27,5	6.303,72 €
Migliore Cristina	RTDA	BIO/17	2318/1797848	2021	Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas	Co-first	3	1			4			0,00 €



## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =punti0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Migliore Cristina	RTDA	BIO/17	2318/1797873	2021	Cancer-associated fibroblasts promote aggressive gastric cancer phenotypes via heat shock factor 1-mediated secretion of extracellular vesicles		3	0	0,5		1,5			0,00 €
Migliore Cristina	RTDA	BIO/17	2318/1798146	2020	Potential role of two novel agonists of thyroid hormone receptor-β on liver regeneration		2	0			2			0,00 €
Migliore Cristina	RTDA	BIO/17	2318/1717860	2019	A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits		3	0	0,5		1,5			0,00 €
Migliore Cristina	RTDA	BIO/17	2318/1671637	2018	miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling		3	1			4			0,00 €
Migliore Cristina	RTDA	BIO/17	2318/1664042	2018	Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts		1	0	0,5		0,5			0,00 €
Migliore Cristina	RTDA	BIO/17	2318/1589685	2017	Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort		3	0	0,5		1,5			0,00 €
Migliore Cristina	RTDA	BIO/17	2318/1660549	2017	YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC	Co-first	2	1			3			0,00 €
Migliore Cristina	RTDA	BIO/17												0,00 €
Monica Valentina	RTDA	BIO/10	2318/1763075	2020	Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells	No fondi.	2	0	0,5		1	9,25	11,5625	2.650,43 €
Monica Valentina	RTDA	BIO/10	2318/1775041	2020	A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome		0,5	0	0,5		0,25			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1775041	2020	Activation of RSK by phosphomimetic substitution in the activation loop is prevented by structural constraints		3	0	0,5		1,5			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1729756	2019	Dynamic Interplay between Pericytes and Endothelial Cells during Sprouting Angiogenesis		1	0			1			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1650666	2018	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.		3	0	0,5		1,5			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1596074	2017	Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.		3	1			4			0,00 €
Monica Valentina	RTDA	BIO/10												0,00 €
Monica Valentina	RTDA	BIO/10												0,00 €
Monica Valentina	RTDA	BIO/10												0,00 €
Monica Valentina	RTDA	BIO/10												0,00 €
Passiglia Francesco	PA	MED/06	2318/1770085	2020	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations	Fondi attivi (CRT)	3	0		0,5	1,5	22,5	22,5	5.157,59 €
Passiglia Francesco	PA	MED/06	2318/1797359	2021	Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A systematic Review and Metanalysis		3	1		0,5	2			0,00 €
Passiglia Francesco	PA	MED/06	2318/1851162	2021	Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC ? A trial level metanalysis in PD-L1 selected subgroups		1	1		0,5	1			0,00 €
Passiglia Francesco	PA	MED/06	2318/1797358	2021	Repositioning PARP inhibitors in the treatment of thoracic malignancies		3	1		0,5	2			0,00 €

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

[illegible]

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =punti0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Ramondetti Cristina	TA													0,00 €
Ramondetti Cristina	TA													0,00 €
Ramondetti Cristina	TA													0,00 €
Ramondetti Cristina	TA													0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1792716			Fondi attivi, Airc. First	3	1			4	19,5	19,5	4.469,91 €
Russo Mariangela	RTDB	BIO/17	2318/1728652				3	0	0,5		1,5			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1725664			Co-first	3	1			4			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1675615				3	0	0,5		1,5			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1675614			First	3	1			4			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1660203				3	0	0,5		1,5			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1622761			First	2	1			3			0,00 €
Russo Mariangela	RTDB	BIO/17												0,00 €
Russo Mariangela	RTDB	BIO/17												0,00 €
Russo Mariangela	RTDB	BIO/17												0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1858947	2021	NTRK Gene Fusion Detection in Atypical Spitz Tumors	Fondi attivi	2	0	0,5		1	11,5	11,5	2.636,10 €
Senetta Rebecca	RTDB	MED/08	2318/1795380	2021	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition		3	0	0,5		1,5			0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1792813	2021	The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI)		2	0	0,5		1,5			0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1762340	2020	Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma.		3	0	0,5		1,5			0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1762342	2020	Likelihood of finding melanoma when removing a melanocytic lesion with peripheral clods.	Letter material su tutte la banche dati	0	0			0			0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1759688	2019	Microenvironment in cutaneous melanomas: a gene expression profile study may explain the role of histological regression	Letter material su tutte la banche dati	0	0			0			0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1695898	2019	TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk.		2	0	0,5		1			0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1658900	2018	Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients.		3	0	0,5		1,5			0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1642129	2017	Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer.		3	0	0,5		1,5			0,00 €
Senetta Rebecca	RTDB	MED/08	2318/1647761	2017	Androgen receptor status predicts development of brain metastases in ovarian cancers.	Co-first	1	1			2			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1790637	2021	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma	Fondi attivi	2	0	0,5		1	15,5	15,5	3.553,01 €
Taulli Riccardo	PA	BIO/10	2318/1787263	2021	IcBα targeting promotes oxidative stress-dependent cell death.		3	0	0,5		1,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1794750	2020	Future perspectives from lung cancer pre-clinical models: new treatments are coming?	Last	2	1		0,5	1,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1737284	2020	P53 vs NF-κB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa		3	0		0,5	1,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1747161	2020	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma		2	0	0,5		1			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1737289	2020	Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets	co-last	2	1			3			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1719484	2020	Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia		1	0	0,5		0,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1635932	2017	Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones	corresponding author	1	1			2			0,00 €

## Valutazione Linea Premialità Pubblicazioni Ricerca Locale 2022

Riduzione + di										Punti	Punteggio				
Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	10 autori =puntix0,5	Riduzione review	Totale	pubblicazioni	ricercatore	Finanziamento	
Taulli Riccardo	PA	BIO/10	2318/1653399	2017	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment	Last	2	1			3			0,00 €	
Taulli Riccardo	PA	BIO/10	2318/1636131	2017	Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia		1	0		0,5	0,5			0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
														0,00 €	
Legenda colori												Totale punti		523,50	118.330,28 €